Hangzhou Just Biotherapeutics completed a $35 million Series B+ round to develop its global antibody and recombinant protein biologic drug portfolio. The funding is in addition to the $57 million B round announced last year. Formed as a JV with Just Bio of Seattle, Hangzhou Just is led by industry veterans who want to optimize development and manufacturing of biologic drugs, making the products more affordable. Hillhouse Capital of
Share this with colleagues:
Original Article: Hangzhou Just Bio Raises $35 Million for Biologics in B+ Round